市場調查報告書
商品編碼
1500568
尿液檢查市場:按產品類型、應用、最終用途分類 - 2024-2030 年全球預測Urinalysis Market by Product (Consumables, Instruments), Test Type (Biochemical Urinalysis, Pregnancy & Fertility Tests, Sediment Urinalysis), Application, End-Use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
尿液檢查市場規模預計2023年為43億美元,2024年達到45.3億美元,預計2030年將達到63.7億美元,複合年成長率為5.76%。
尿液檢查是對尿液樣本進行的測試,通常用於醫學篩檢和診斷。該測試包括評估尿液的物理、化學和微觀特性的各種元素。分析這些特徵可以幫助檢測各種疾病,例如尿道感染、腎臟疾病和糖尿病。通常有三種類型的測試:目視測試,查看尿液的顏色和透明度;化學測試,尋找蛋白質、葡萄糖和血液等物質;以及顯微鏡測試,尋找尿液中看不見的因素。細菌的存在,將進行兩項測試。全球範圍內腎臟疾病和尿道感染的增加導致臨床實踐中照護現場(POC) 系統的使用增加。這些系統提供快速且有效率的分析,導致醫院和實驗室的採用增加,支持市場成長。然而,需要提高人們對定期健康檢查重要性的認知,並且缺乏熟練的實驗室工作人員正在阻礙尿液檢查市場的成長。用於檢測尿道感染的自動分析儀的開發是一項重要的技術進步,可以提供快速、準確的檢測。隨著醫療保健提供者擴大採用這些高效可靠的系統,這將改善患者照護並為市場擴張開闢新的機會。這些創新預計將透過滿足對及時有效的診斷解決方案不斷成長的需求來推動市場擴張。
主要市場統計 | |
---|---|
基準年[2023] | 43億美元 |
預計年份 [2024] | 45.3億美元 |
預測年份 [2030] | 63.7億美元 |
複合年成長率(%) | 5.76% |
區域洞察
由於先進的醫療基礎設施、高額醫療支出以及對預防性醫療的高度重視,美洲的尿液檢查市場非常強勁,尤其是在美國和加拿大。腎臟病和糖尿病等慢性疾病的盛行率不斷上升,需要定期尿液檢查,這對市場成長做出了重大貢獻。政府和醫療機構加強診斷服務的努力正在支持該地區尿液檢查市場的擴張。由於中國和印度等醫療意識的提高、人口的成長和經濟的開拓,亞太地區的尿液檢查市場呈現快速成長。亞太地區有大量糖尿病患者,透過尿液檢查頻繁監測血糖濃度的需求也推動了市場成長。此外,由於勞動力限制和對高效醫療保健解決方案的需求,向自動化尿液檢查系統的轉變也加劇了這種成長。由於醫療保健意識的提高、診斷技術的進步以及糖尿病和尿道感染等疾病盛行率的上升,歐洲、中東和非洲地區的尿液檢查市場正在呈現成長。歐盟用於改善診斷技術的研究經費反映了其改善成員國醫療保健成果的承諾。隨著人們對尿道感染和糖尿病等疾病的認知不斷提高,非洲尿液檢查市場也逐漸擴大。
FPNV定位矩陣
FPNV 定位矩陣對於評估尿液檢查市場供應商的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對尿液檢查市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
戰略分析和建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對目前在尿液檢查市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[187 Pages Report] The Urinalysis Market size was estimated at USD 4.30 billion in 2023 and expected to reach USD 4.53 billion in 2024, at a CAGR 5.76% to reach USD 6.37 billion by 2030.
Urinalysis is a test conducted on a urine sample and is commonly used for medical screening and diagnosis. The test encompasses various components that assess the urine's physical, chemical, and microscopic properties. By analyzing these properties, the test helps in detecting various disorders, such as urinary tract infections, kidney disease, and diabetes. The process typically involves three examinations: a visual exam, which observes the urine's color and clarity; a chemical exam, which tests chemically for substances such as protein, glucose, and blood; and a microscopic exam, which looks for cells, bacterial presence, and other elements that are not visible to the naked eye. The increasing incidence of kidney diseases and urinary tract infections globally leads to higher use of point-of-care urinalysis systems in clinical settings. These systems offer quick and efficient analysis, which propels their adoption in hospitals and labs, thus supporting the market's growth. However, the need for more awareness about the importance of regular health checkups and a shortage of skilled laboratory staff hinder the growth of the urinalysis market. The development of automated analyzers for detecting urinary tract infections represents a significant technological advancement, offering rapid and accurate testing. This improves patient care and opens up new opportunities for market expansion as healthcare providers increasingly adopt these efficient and reliable systems. These innovations are expected to propel market expansion by fulfilling the rising demand for timely and effective diagnostic solutions.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 4.30 billion |
Estimated Year [2024] | USD 4.53 billion |
Forecast Year [2030] | USD 6.37 billion |
CAGR (%) | 5.76% |
Regional Insights
In the Americas, particularly in the United States and Canada, the urinalysis market is robust due to the advanced healthcare infrastructure, high healthcare spending, and a strong focus on preventive care. The growing prevalence of chronic diseases, such as kidney disorders and diabetes requiring regular urine tests, contributes significantly to the market growth. Government and health organizations' initiatives to enhance diagnostic services support the expansion of the urinalysis market in this region. The Asia-Pacific region is showcasing rapid growth in the urinalysis market, driven by rising healthcare awareness, increasing population, and economic development in countries such as China and India. The Asia-Pacific region's large diabetic population, which requires frequent glucose level monitoring through urine tests, also propels market growth. In addition, the shift towards automated urinalysis systems due to labor constraints and the need for efficient healthcare solutions accentuates this growth. The urinalysis market in the EMEA region is showcasing growth owing to increasing healthcare awareness, advancements in diagnostic technologies, and a rising prevalence of diseases, including diabetes and urinary tract infections. EU funding for research in improving diagnostic technologies reflects a committed approach to enhancing healthcare outcomes across member states. The African urinalysis market is gradually growing with increased awareness about diseases such as urinary tract infections and diabetes.
Market Insights
The market dynamics represent an ever-changing landscape of the Urinalysis Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Urinalysis Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Urinalysis Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
AixMed and CorePlus Collaborate on Innovative Urine Analysis Research
AixMed partnered with CorePlus for an innovative study focusing on urine analysis to enhance diagnostic accuracy for various diseases. This partnership leverages CorePlus laboratories' capabilities and AixMed's expertise in medical diagnostics technology to revolutionize how diseases are detected and monitored potentially. This initiative aims to contribute valuable insights into disease mechanisms and patient health management. [Published On: 2024-04-18]
Toyoda Gosei Invests in Yuurea Inc. for Advancement in Urine Analysis Technology
Toyoda Gosei Co., Ltd. strategically invested in Yuurea Inc., an innovative startup specializing in the development of urine test kits aimed at early detection of eating disorders. Yuurea Inc.'s urine test kits represent a significant advancement in medical diagnostics, offering a non-invasive and timely method for identifying potential eating disorders, thereby facilitating earlier intervention and treatment. [Published On: 2024-03-25]
Medtronic's Strategic Initiative to Address Urinary Incontinence with New Venture
Medtronic, a medical technology, service, and solutions provider, recently unveiled a new venture specifically aimed at advancing treatments for urinary incontinence, expanding its portfolio in medical technology solutions. This develops the company's commitment to address widespread health concerns by investing in innovative and effective treatments. [Published On: 2023-04-03]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Urinalysis Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Urinalysis Market, highlighting leading vendors and their innovative profiles. These include 77 Elektronika Kft., Abbott Laboratories, ACON Laboratories, Inc. by Inverness Medical, AdvaCare Pharma, Alphatec Scientific E.I.R.L., Analyticon Biotechnologies GmbH by BRAIN Biotech AG, Anamol Laboratories Pvt. Ltd., ARKRAY, Inc., Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., Bioway Biotechnology Co., Ltd., Cardinal Health, Inc., Contec Medical Systems Co., Ltd., Dirui Industrial Co., Ltd., EKF DIAGNOSTICS HOLDINGS PLC, Erba Group, F. Hoffmann-La Roche Ltd., Kova International, Inc. by LGC Limited, MACHEREY-NAGEL GmbH & Co. KG, Medsource Ozone Biomedicals Pvt. Ltd., Quidel Corporation, Randox Laboratories Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthcare GmbH, Sweet Cures Nutra, Sysmex Corporation, Teco Diagnostics, Thermo Fisher Scientific Inc., URIT Medical Electronic Group Co., Ltd, and Woodley Equipment Company Ltd..
Market Segmentation & Coverage
chronic diseases